Novel Drug Eases Uremic Pruritus
In a phase 3 trial, difelikefalin, a kappa opioid receptor agonist, significant decreased itching and improved itching-related quality of life among dialysis patients suffering from pruritus.
Dialysis
ESRD Due to Membranous Nephropathy Predicts Better Outcomes
Compared with other causes of end-stage renal disease, membranous nephropathy is associated with superior survival on dialysis and following kidney transplantation, investigators reported.
Black Race in the Dialysis Population Lowers PCI Odds
Despite Medicare coverage, black patients on dialysis are less likely than their white counterparts to undergo percutaneous coronary intervention.
Narrowing Seen in Racial/Ethnic Differences in Home Dialysis Use
Home dialysis use increased in all groups; racial, ethnic differences decreased from 2005 to 2013
Maintaining Work During Dialysis Tied to Higher Survival
Employment rates low among patients initiating dialysis
Epilepsy Tied With Increased Death Risk in Dialysis
Nearly 1 in 10 patients with end-stage renal disease (ESRD) has epilepsy, and the disorder as well as a commonly prescribed medication for it are associated with an increased risk of premature death, a new study found. According to the authors, seizures are a known complication of uremia, hemodialysis, medications such as antibiotics, and comorbidities…
Volume Overload Common at PD Initiation, Predicts Higher Death Risk
In a study, volume overload tended to improve by 6 months after peritoneal dialysis initiation, then stabilize.
More Than Half of Older Patients Die Within 1 Year of Starting Dialysis
In a study, 54.5% of Medicare patients died within 1 year of dialysis initiation, a mortality rate much higher than calculated by the US Renal Data System.
Canagliflozin Lowers ESRD Risk in Diabetic Kidney Disease
In a study of patients with type 2 diabetes and chronic kidney disease, canagliflozin, an SGLT2 inhibitor, decreased the risk of end-stage renal disease by 32% compared with placebo.
Spironolactone Has No Effect on LVM in Hemodialysis Patients
Patients treated with the mineralocorticoid receptor antagonist had a higher frequency of moderate hyperkalemia compared with placebo recipients.
Next post in Hemodialysis
